Cargando…

HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy

Advanced studies have shown a biological correlation between hepatitis B virus (HBV) and B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL). Patients with DLBCL infected with HBV (HBV-associated DLBCL) are clinically characterized by an advanced clinical stage, poor response to front-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Xin, Young, Ken H., Bai, Ou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360167/
https://www.ncbi.nlm.nih.gov/pubmed/37483605
http://dx.doi.org/10.3389/fimmu.2023.1216610
_version_ 1785076042898079744
author Wan, Xin
Young, Ken H.
Bai, Ou
author_facet Wan, Xin
Young, Ken H.
Bai, Ou
author_sort Wan, Xin
collection PubMed
description Advanced studies have shown a biological correlation between hepatitis B virus (HBV) and B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL). Patients with DLBCL infected with HBV (HBV-associated DLBCL) are clinically characterized by an advanced clinical stage, poor response to front-line immunochemotherapy regimens, and worse clinical prognosis. HBV-associated DLBCL often exhibits abnormal activation of the nuclear factor kappa B pathway as well as mutations in oncogenes, including Myc and BCL-6. Currently, there is no consensus on any specific and effective treatment for HBV-associated DLBCL. Therefore, in this review, we comprehensively and mechanistically analyzed the natural history of HBV infection and immunity, including HBV-mediated oncogenes, immune escape, epigenetic alterations, dysregulated signaling pathways, and potential therapeutic approaches for HBV-associated DLBCL. We hope that an improved understanding of the biology of HBV-associated DLBCL would lead to the development of novel therapeutic approaches, enhance the number of effective clinical trials, and improve the prognosis of this disease.
format Online
Article
Text
id pubmed-10360167
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103601672023-07-22 HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy Wan, Xin Young, Ken H. Bai, Ou Front Immunol Immunology Advanced studies have shown a biological correlation between hepatitis B virus (HBV) and B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL). Patients with DLBCL infected with HBV (HBV-associated DLBCL) are clinically characterized by an advanced clinical stage, poor response to front-line immunochemotherapy regimens, and worse clinical prognosis. HBV-associated DLBCL often exhibits abnormal activation of the nuclear factor kappa B pathway as well as mutations in oncogenes, including Myc and BCL-6. Currently, there is no consensus on any specific and effective treatment for HBV-associated DLBCL. Therefore, in this review, we comprehensively and mechanistically analyzed the natural history of HBV infection and immunity, including HBV-mediated oncogenes, immune escape, epigenetic alterations, dysregulated signaling pathways, and potential therapeutic approaches for HBV-associated DLBCL. We hope that an improved understanding of the biology of HBV-associated DLBCL would lead to the development of novel therapeutic approaches, enhance the number of effective clinical trials, and improve the prognosis of this disease. Frontiers Media S.A. 2023-07-07 /pmc/articles/PMC10360167/ /pubmed/37483605 http://dx.doi.org/10.3389/fimmu.2023.1216610 Text en Copyright © 2023 Wan, Young and Bai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wan, Xin
Young, Ken H.
Bai, Ou
HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy
title HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy
title_full HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy
title_fullStr HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy
title_full_unstemmed HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy
title_short HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy
title_sort hbv-associated dlbcl of poor prognosis: advance in pathogenesis, immunity and therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360167/
https://www.ncbi.nlm.nih.gov/pubmed/37483605
http://dx.doi.org/10.3389/fimmu.2023.1216610
work_keys_str_mv AT wanxin hbvassociateddlbclofpoorprognosisadvanceinpathogenesisimmunityandtherapy
AT youngkenh hbvassociateddlbclofpoorprognosisadvanceinpathogenesisimmunityandtherapy
AT baiou hbvassociateddlbclofpoorprognosisadvanceinpathogenesisimmunityandtherapy